Articles

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases. 

Dangers, Benefits of Biologics Must Be Carefully Weighed

Videos

Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.

Upadacitinib for the Treatment of Atopic Dermatitis

There may be an association between atopic dermatitis severity and diagnosis of ocular disease, such as conjunctivitis.

Dupilumab Linked to Increased Ocular Disease Prevalence in AD Patients

A new generation of inhibitors take aim at key sources of inflammation.

Emerging Biologics Make Waves in AD 

Dermatologists have a variety of topicals to choose from, but other options are on the horizon to add to this armamentarium.

Current and Upcoming Topicals in the Pipeline for AD 

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.  

Off-label Biologics Target Wide Range of Skin Diseases

A study presented at the American Academy of Dermatology Virtual Meeting Experience 2021 exhibited new safety and efficacy data for etrasimod as a potential treatment for atopic dermatitis.

Etrasimod Demonstrates New Safety, Efficacy Data for AD in Phase 2 Study

Interim analysis of data from the ECZTEND study evaluating the long-term safety, efficacy, and tolerability of tralokinumab for treatment of atopic dermatitis was presented at AAD VMX 2021.

 Tralokinumab Safe, Effective for Long-Term Treatment of Atopic Dermatitis 

A phase 3 trial produced results on the efficacy of different doses of the JAK1 inhibitor.

Abrocitinib Effective as Flexible Dose for Atopic Dermatitis

Nemolizumab shows positive results according to a recently published post hoc analysis of a phase 2b trial evaluating the drug vs placebo in adult patients with moderate to severe atopic dermatitis (AD). 